Childhood Hodgkin's Survivor Studies to Become a Pediatric Oncologist
21 year old Ethan Helm of Mabelvale, Arkansas has a dream: to become a pediatric oncologist (a children's cancer doctor) to help people affected by Hodgkin's Lymphoma. Ethan knows alot about Hodgkin's as he was diagnosed at age 15 with cancer.
Today Ethan has been in remission for 5 years and he is studing biology at Wake Forest College in Chicago on the road to medical school. The American Cancer Society awarded him a $1000 scholarship to help him achieve his goal. "Receiving the scholarship is quite a blessing," Helm said. "The school I go to is very expensive, and if it weren't for scholarships, there is no way I could attend it. My parents can't afford to pay my way, so the ACS scholarship is really helping me get a good education."
After he becomes a doctor, he is "thinking about going to Africa or somewhere else" where cancer treatment isn't as advanced "to help people."
You can read more about Ethan in the Benton Courier.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
